Batavia Biosciences, a contract development and manufacturing organization (CDMO), has released Amalia, a GMP-ready manufacturing facility in Bilthoven, Netherlands, expanding capabilities to deliver clinical manufacturing of viral vaccines and viral vectors. 

The facility houses advanced equipment and adheres to stringent quality standards for viral vector and vaccine development and production.

Amalia maintains up to Grade B cleanroom standards to ensure sterile and safe production environments. Equipped with two upstream suites, the facility is designed for parallel manufacturing of viral vectors and vaccines at volumes reaching 200 liters. Leveraging single-use technologies suitable for suspension and adherent cells, the facility operates under strict Biosafety Level 2 (BSL-2) protocols, enabling the safe handling of pathogens such as Measles, Herpes Simplex, and Influenza.

Batavia plans launch a more extensive, state-of-the-art facility in Leiden to complement and eventually supersede Amalia with a daily production capacity planned to reach 576,000 vials.

Menzo Havenga, CEO Batavia Biosciences, said, “The release of this facility is a significant achievement for our company. It supports Batavia Biosciences’ mission of being a center of excellence able to support customers’ vital efforts to bring essential medical countermeasures from the lab to the patients who need them most. This facility is critical to increasing clinical manufacturing capacity to align with market needs and support epidemic preparedness.”